People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

In this final part of a recent interview with Jonathan Strober, MD, UCSF Benioff Children's Hospital and phase 2/3 ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

June is Myasthenia Gravis Awareness month. We are trying to raise awareness through various activities. One such activity is ...

The Phase 3 AURORA trial tests Descartes-08 against a placebo in patients with acetylcholine receptor autoantibody positive myasthenia gravis. How many participants are enrolled in the AURORA trial?

Despite acknowledging that efgartigimod (Vyvgart), can 'improve symptoms and people’s ability to carry out their normal ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis Global MG Community turns Awareness into Action to ...